# Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

> **NCT06712927** · PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma
- Brain Metastases

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab + Relatlimab FDC

## Key facts

- **NCT ID:** NCT06712927
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2026-11
- **Final completion:** 2030-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712927, "Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT06712927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*